東曜藥業-B(01875.HK)與濟民可信醫藥附屬簽訂樸欣汀®在中國大陸市場獨家推廣服務協議
格隆匯12月21日丨 東曜藥業-B(01875.HK)公吿，公司全資附屬公司東曜藥業有限公司與江西濟民可信醫藥產業投資有限公司全資附屬公司江西濟鑫醫藥有限公司(作為推廣服務方，"濟鑫醫藥")就樸欣汀®(貝伐珠單抗注射液，擬使用英文商品名稱：Pusintin®，"該產品")在中國大陸市場推廣訂立獨家推廣服務協議，據此，濟鑫醫藥獲得該產品在推廣服務區域內的獨家推廣權，而蘇州東曜繼續擁有該產品在推廣服務區域內除推廣權外的所有權益。
依據該協議，蘇州東曜將該產品在推廣服務區域內的獨家推廣權授予濟鑫醫藥。在遵守該協議條款的基礎上，濟鑫醫藥及其指定的關聯方有權在推廣服務區域內利用該產品商標對該產品提供獨家推廣服務。
該協議的簽署，旨在將該產品通過蘇州東曜和濟鑫醫藥的緊密合作快速推向市場，提供高品質的藥物惠及中國患者。本集團與濟民可信醫藥及其附屬公司在產品市場推廣及CDMO業務領域進行了良好的合作。該協議的簽訂將有利於提升該產品品牌影響力，有力推動市場推廣。
樸欣汀®(貝伐珠單抗注射液，擬使用英文商品名稱：Pusintin®)是由蘇州東曜自主開發的生物抗體藥物，於近期獲得中國國家藥品監督管理局的上市批准，用於治療晚期、轉移性或複發性非鱗狀非小細胞肺癌(nsNSCLC)和轉移性結直腸癌(mCRC)。樸欣汀®是安維汀®(Avastin)的生物類似藥，後者在中國已獲批用於治療nsNSCLC、mCRC、膠質母細胞瘤(GBM)、肝細胞癌(HCC)、卵巢癌和宮頸癌。樸欣汀®採用本集團自主開發的灌注－批式混合培養技術(PB-Hybrid®技術)進行單抗藥物商業化生產，可通過25升WAVE生物反應器進行種子擴增，並直接擴展到2,000升規模的生物反應器，該技術相較於行業慣用技術，簡化了工藝流程、縮短生產週期、降低生產成本，更具成本優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
